SunLink Health Systems Inc - Asset Resilience Ratio

Latest as of March 2025: 42.73%

SunLink Health Systems Inc (SSY) has an Asset Resilience Ratio of 42.73% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore SunLink Health Systems Inc assets under control for the complete picture of this company's asset base.

Liquid Assets

$7.47 Million
Cash + Short-term Investments

Total Assets

$17.47 Million
All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2012–2024)

This chart shows how SunLink Health Systems Inc's Asset Resilience Ratio has changed over time. See debt-free asset ratio of SunLink Health Systems Inc to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down SunLink Health Systems Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SSY stock market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $7.47 Million 42.73%
Short-term Investments $0.00 0%
Total Liquid Assets $7.47 Million 42.73%

Asset Resilience Insights

  • Very High Liquidity: SunLink Health Systems Inc maintains exceptional liquid asset reserves at 42.73% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

SunLink Health Systems Inc Industry Peers by Asset Resilience Ratio

Compare SunLink Health Systems Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Dashenlin Pharm Grp Co Ltd
SHG:603233
Pharmaceutical Retailers 0.80%
d1000 Varejo Farma Participações S.A
SA:DMVF3
Pharmaceutical Retailers 2.05%
Raia Drogasil S.A
SA:RADL3
Pharmaceutical Retailers 0.38%
Empreendimentos Pague Menos S.A
SA:PGMN3
Pharmaceutical Retailers 0.00%
High Tide Inc
V:HITI
Pharmaceutical Retailers 0.03%
Yifeng Pharmacy
SHG:603939
Pharmaceutical Retailers 19.16%
Laobaixing Pharmacy
SHG:603883
Pharmaceutical Retailers 0.01%
Yunnan Hongxiang Yixintang
SHE:002727
Pharmaceutical Retailers 4.78%

Annual Asset Resilience Ratio for SunLink Health Systems Inc (2012–2024)

The table below shows the annual Asset Resilience Ratio data for SunLink Health Systems Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-06-30 34.79% $7.17 Million $20.61 Million +15.51pp
2023-06-30 19.28% $4.49 Million $23.27 Million -12.28pp
2021-06-30 31.56% $9.96 Million $31.56 Million -8.42pp
2020-06-30 39.98% $11.18 Million $27.97 Million +8.28pp
2019-06-30 31.70% $7.74 Million $24.42 Million +18.50pp
2018-06-30 13.20% $3.46 Million $26.18 Million -21.32pp
2017-06-30 34.52% $12.20 Million $35.34 Million +27.25pp
2016-06-30 7.27% $3.26 Million $44.84 Million --
2015-06-30 0.00% $0.00 $57.13 Million --
2014-06-30 0.00% $0.00 $63.85 Million --
2013-06-30 0.24% $160.00K $68.00 Million --
2012-06-30 0.00% $0.00 $79.17 Million --
pp = percentage points

About SunLink Health Systems Inc

NYSE MKT:SSY USA Pharmaceutical Retailers
Market Cap
$7.85 Million
Market Cap Rank
#27619 Global
#5564 in USA
Share Price
$1.12
Change (1 day)
+16.15%
52-Week Range
$0.85 - $1.36
All Time High
$4.85
About

As of August 14, 2025, SunLink Health Systems, Inc. was acquired by Regional Health Properties, Inc. SunLink Health Systems, Inc., through its subsidiaries, provides healthcare products and services in the southeastern United States. The company operates through Healthcare Services and Pharmacy segments. It is also involved in provision of specialty and non-specialty pharmaceutical and biological… Read more